🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — my results so far Page 3

My blood pressure normalization journey — my results so far

FranDenver Tue, Jan 9, 2024 at 7:38 AM 12 replies 2,127 viewsPage 3 of 3
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jan 11, 2024 at 4:41 AM#11
TrialTracker_MD said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 8.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

Last edited: Jan 11, 2024 at 6:41 AM
19 17FitDadDave, RunnerRach, TrialNerd_Beth and 16 others
Reply Quote Save Share Report
traveltech_sara
Member
156
678
Jan 2025
Remote, USA
Jan 12, 2024 at 4:53 PM#12
marco_milano said:
Senior perspective on cardiovascular risk: I'm 67 years old and started this journey skeptically.

Saving this. It is the first explanation that did not require me to already understand it. Taking it to my next appointment.

20 18LarryQC_SD, wanda_boise, NurseAsh_DET and 17 others
Reply Quote Save Share Report
BenResearch_OR
Senior Member
2,456
11,234
Dec 2023
Oregon
Jan 14, 2024 at 5:04 AM#13
TrialTracker_MD said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 8.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 3 of 5 diagnostic criteria to meeting ZERO after 11 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 50" → 36" ✅ Resolved
  2. Triglycerides: 270 → 95 ✅ Resolved
  3. HDL: 34 → 52 ✅ Resolved
  4. Blood pressure: 140/92 → 118/72 ✅ Resolved
  5. Fasting glucose: 120 → 86 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: Jan 14, 2024 at 6:04 AM
21 19Dr.NateNeph, PharmD_Rodriguez, julia.endo and 18 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Jan 15, 2024 at 5:14 PM#14
FranDenver said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 74 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

22 20TirzTom, TrialTracker_MD, JennaRN and 19 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jan 17, 2024 at 5:24 AM#15

Moderator note: reminder that nothing in this thread is medical advice, and that clinical claims need a source.

23 21PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 20 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register